Shares of Evolent Health Inc (NYSE:EVH) have earned a consensus recommendation of “Buy” from the nine ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $14.11.
EVH has been the topic of several research analyst reports. KeyCorp lowered their price target on Evolent Health from $20.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday. They noted that the move was a valuation call. Oppenheimer set a $15.00 price objective on Evolent Health and gave the stock a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research lowered Evolent Health from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price objective (down previously from $16.00) on shares of Evolent Health in a research report on Wednesday, November 27th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $10.15 target price on shares of Evolent Health in a report on Wednesday, November 27th.
Several institutional investors have recently modified their holdings of the company. Aperio Group LLC purchased a new stake in shares of Evolent Health in the 2nd quarter worth $40,000. ETRADE Capital Management LLC purchased a new stake in Evolent Health in the 2nd quarter worth approximately $80,000. DekaBank Deutsche Girozentrale increased its holdings in Evolent Health by 94.4% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 12,061 shares of the technology company’s stock worth $95,000 after acquiring an additional 5,856 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. raised its stake in Evolent Health by 38.4% during the 2nd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 15,500 shares of the technology company’s stock worth $123,000 after acquiring an additional 4,300 shares during the period. Finally, NumerixS Investment Technologies Inc bought a new stake in Evolent Health during the 2nd quarter worth approximately $125,000.
Shares of NYSE EVH traded up $0.12 during trading on Tuesday, reaching $6.73. 273,461 shares of the company traded hands, compared to its average volume of 2,087,676. The stock has a market capitalization of $610.03 million, a PE ratio of -19.23 and a beta of 1.04. The firm has a 50 day simple moving average of $8.39 and a 200-day simple moving average of $8.25. Evolent Health has a 52-week low of $5.50 and a 52-week high of $26.21. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.27.
Evolent Health (NYSE:EVH) last issued its earnings results on Tuesday, November 5th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.03. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.93%. The company had revenue of $220.14 million for the quarter, compared to analysts’ expectations of $217.90 million. During the same quarter last year, the company posted ($0.04) earnings per share. The firm’s quarterly revenue was up 46.8% on a year-over-year basis. As a group, research analysts predict that Evolent Health will post -0.95 EPS for the current year.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Story: How liquidity affects the bid-ask spread
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.